Tricia Fairchild, MD
Family Medicine · Davenport, IANPI 1609169499
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 27 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 12 manufacturers reported payments, led by Organogenesis Inc. at 43.2% of the total. Reporting peaked in 2019 at $215 and has fallen 58.6% since, to $89 in 2025.
Across 27 payments — averaging $20.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Organogenesis Inc.$241
- Smith+Nephew$91
- Medline Industries LP$57
- Amgen$34
- Acera Surgical, Inc.$28
- Kerecis Limited$25
- plus $83 from 6 others
What the payments were for
- Food & beverage$559100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Organogenesis Inc. | 11 | $241 |
| Smith+Nephew | 4 | $91 |
| Medline Industries LP | 2 | $57 |
| Amgen | 2 | $34 |
| Acera Surgical, Inc. | 1 | $28 |
| Kerecis Limited | 1 | $25 |
| Solventum Corporation | 1 | $21 |
| Integra Lifesciences Corporation | 1 | $14 |
| Johnson & Johnson | 1 | $14 |
| Merck | 1 | $12 |
| Eisai Inc. | 1 | $12 |
| Melinta Therapeutics, LLC | 1 | $12 |
How this compares
$559 in reported general payments places this provider in the 75th percentile of 1,357 family medicine providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 12 | $8,198 |
| Gabapentin | 33 | $586 |
| Atorvastatin Calcium | 51 | $486 |
| Duloxetine Hcl | 13 | $400 |
| Losartan Potassium | 45 | $328 |
| Rosuvastatin Calcium | 22 | $278 |
| Esomeprazole Magnesium | 12 | $264 |
| Amlodipine Besylate | 39 | $252 |
| Lisinopril | 32 | $193 |
| Omeprazole | 20 | $191 |
| Tizanidine Hcl | 11 | $82 |
| Metformin Hcl ErMetformin Hcl | 15 | $62 |
| Pantoprazole Sodium | 15 | $61 |
| Levothyroxine Sodium | 32 | $56 |
| Alendronate Sodium | 11 | $35 |
Paid to pharmacies, not to this prescriber.
Other family medicine in Davenport
- Linda JagerDavenport$7K
- Kirk PetersonHuxley$576K
- Nicholas GoetschWaterloo$525K
- Stephen HarrisonClinton$249K
- Thomas RossDes Moines$170K
- Yogesh ShahDes Moines$159K
- Leslie George PaulsenMuscatine$136K
- Dylan LoweDes Moines$105K
- Michael AbouassalyWest Burlington$88K
- Kevin DeregnierWinterset$68K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.